ArticleBMC microbiology2026
Colonization with Carbapenemase producing Enterobacterales (CPE) and associated alteration in microbiota composition in a tertiary care hospital in Egypt.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rising incidence of carbapenemase producing Enterobacterales (CPE)s, represents an urgent health threat due to their raised morbidity and mortality consequences. Colonization of CPE represents an important vehicle for hospital acquired infections. Microbiota dysbiosis, especially in critically ill patients, is a risk factor associated with CPE-colonized infections. In this study we aimed to characterize and assess the rate of colonization with CPE, and the possibility of subsequent infection. Also, to investigate the role of microbiota dysbiosis as a potential risk factor for colonization with CPE by comparing the gut niche in colonized patients versus non-colonized patients.
methodsRectal swabs and stools were collected from 70 patients attending Hepatogastroentrology Department at TBRI Hospital on their first 72 h of admission and during their hospital stay. Incidence of infection with CPE was followed up in the same patients with relevant clinical specimens, mainly urine culture and sensitivity. Rectal swabs were cultured on chromogenic agar media, whereas clinical specimens were cultured following microbiological methods. Species identification and antibiotic sensitivity testing were performed using Vitek-2 compact system on suspected CPE isolates, as well as detection of carbapenemase genes by conventional PCR for detection of blaNDM, blaOXA-48, blaVIM, blaKPC and blaIMP. The 16S rRNA profiling was used for identification of gut microbiota using Illumina Miseq Sequencing System (Illumina). EzBioCloud 16S rRNA database was used for taxonomic assignment.
resultsCPE carriage was found in 22.85% (n = 16) of included patients. blaNDM was found predominantly in 75% (n = 12) of the isolates followed by blaOXA-48 in 62.5% (10/16). BlaVIM was found in two isolates with blaNDM and blaOXA-48, whereas blaKPC and blaIMP were not detected in all tested isolates.Urinary tract infection associated with CRE colonization was detected in 12.5% (n = 2). Significant predominance of Proteobacteria was found in stool of CPE carriers with p < 0.03.
conclusionOur results confirm the continuous pervasiveness of carbapenem resistance in our region. Alteration in microbiota and the abundance of Proteobacteria in CPE carriers may indicate a predisposition to inflammatory states in those patients and the requirement to further studies on the associated health effect. Efficient antimicrobial stewardships, strict infection control measures, and active surveillance programs are mandatory to limit the spread and subsequent infection with CPE isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.